Sign In
Buy MLSS
Milestone Scientific Earnings Calls
| Release date | May 13, 2026 |
| EPS estimate | -$0.0150 |
| EPS actual | -$0.0100 |
| EPS Surprise | 33.33% |
| Revenue estimate | 2.252M |
| Revenue actual | 2.162M |
| Revenue Surprise | -3.99% |
| Release date | Mar 31, 2026 |
| EPS estimate | -$0.0150 |
| EPS actual | -$0.0200 |
| EPS Surprise | -33.33% |
| Revenue estimate | 2.31M |
| Revenue actual | 2.064M |
| Revenue Surprise | -10.63% |
| Release date | Nov 13, 2025 |
| EPS estimate | -$0.0150 |
| EPS actual | -$0.0100 |
| EPS Surprise | 33.33% |
| Revenue estimate | 2.31M |
| Revenue actual | 2.36M |
| Revenue Surprise | 2.19% |
| Release date | Aug 14, 2025 |
| EPS estimate | -$0.0100 |
| EPS actual | -$0.0200 |
| EPS Surprise | -100.00% |
| Revenue estimate | 2.3M |
| Revenue actual | 2.323M |
| Revenue Surprise | 1.02% |
Last 4 Quarters for Milestone Scientific
Below you can see how MLSS performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 14, 2025 |
| Price on release | $0.579 |
| EPS estimate | -$0.0100 |
| EPS actual | -$0.0200 |
| EPS surprise | -100.00% |
| Date | Price |
|---|---|
| Aug 08, 2025 | $0.640 |
| Aug 11, 2025 | $0.600 |
| Aug 12, 2025 | $0.624 |
| Aug 13, 2025 | $0.602 |
| Aug 14, 2025 | $0.579 |
| Aug 15, 2025 | $0.650 |
| Aug 18, 2025 | $0.631 |
| Aug 19, 2025 | $0.600 |
| Aug 20, 2025 | $0.598 |
| 4 days before | -9.43% |
| 4 days after | 3.25% |
| On release day | 12.22% |
| Change in period | -6.49% |
| Release date | Nov 13, 2025 |
| Price on release | $0.370 |
| EPS estimate | -$0.0150 |
| EPS actual | -$0.0100 |
| EPS surprise | 33.33% |
| Date | Price |
|---|---|
| Nov 07, 2025 | $0.400 |
| Nov 10, 2025 | $0.380 |
| Nov 11, 2025 | $0.371 |
| Nov 12, 2025 | $0.369 |
| Nov 13, 2025 | $0.370 |
| Nov 14, 2025 | $0.330 |
| Nov 17, 2025 | $0.312 |
| Nov 18, 2025 | $0.316 |
| Nov 19, 2025 | $0.320 |
| 4 days before | -7.48% |
| 4 days after | -13.51% |
| On release day | -10.81% |
| Change in period | -19.98% |
| Release date | Mar 31, 2026 |
| Price on release | $0.288 |
| EPS estimate | -$0.0150 |
| EPS actual | -$0.0200 |
| EPS surprise | -33.33% |
| Date | Price |
|---|---|
| Mar 25, 2026 | $0.300 |
| Mar 26, 2026 | $0.280 |
| Mar 27, 2026 | $0.266 |
| Mar 30, 2026 | $0.304 |
| Mar 31, 2026 | $0.288 |
| Apr 01, 2026 | $0.299 |
| Apr 02, 2026 | $0.284 |
| Apr 06, 2026 | $0.290 |
| Apr 07, 2026 | $0.282 |
| 4 days before | -3.97% |
| 4 days after | -2.08% |
| On release day | 3.68% |
| Change in period | -5.97% |
| Release date | May 13, 2026 |
| Price on release | $0.350 |
| EPS estimate | -$0.0150 |
| EPS actual | -$0.0100 |
| EPS surprise | 33.33% |
| Date | Price |
|---|---|
| May 07, 2026 | $0.469 |
| May 08, 2026 | $0.457 |
| May 11, 2026 | $0.400 |
| May 12, 2026 | $0.350 |
| May 13, 2026 | $0.350 |
| May 14, 2026 | $0.336 |
| May 15, 2026 | $0.327 |
| May 18, 2026 | $0.325 |
| May 19, 2026 | $0.347 |
| 4 days before | -25.29% |
| 4 days after | -0.97% |
| On release day | -4.25% |
| Change in period | -26.01% |
Milestone Scientific Earnings Call Transcript Summary of Q1 2026
Milestone Scientific reported Q1 2026 results with stable revenue of ~$2.2M and strong gross margins (72.3%). Management reduced operating expenses by ~$1.3M year-over-year (>30%), narrowing operating loss to $828k and net loss to $840k (both improved ~58% YoY). Key growth drivers: CompuFlo (medical) revenue more than doubled year-over-year (Q1 CompuFlo revenue ~$108k) with growing clinical interest, 152 digital leads, 8 physician partners and >50 claims submitted across three MACs; dental remains the backbone with an expanding ambassador program (73 active ambassadors, 25 new demos). International registration efforts (notably India, Mexico, Japan) are in process and could contribute late in the year. The company completed a $2.15M financing after quarter-end to fund sales expansion, inventory and digital marketing. Management reaffirmed 2026 revenue guidance of $9.8M–$10.2M (double-digit growth) and targets cash flow breakeven in early 2027, contingent on disciplined spending and progress on reimbursement (Medicare/MAC) for CompuFlo.
